Curated News
By: NewsRamp Editorial Staff
August 06, 2024
Clene to Present at Canaccord Genuity Conference
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Clene Inc. will present at Canaccord Genuity 44th Annual Growth Conference, offering potential investment opportunities.
- Clene Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function through investigational first-in-class therapy.
- Clene Inc.'s focus on treating neurodegenerative diseases such as ALS and MS has the potential to improve the lives of patients and their families.
- Clene Inc. is set to present at the Canaccord Genuity 44th Annual Growth Conference, offering a unique insight into the company's innovative approach to neurodegenerative disease treatment.
Impact - Why it Matters
This news matters as it highlights Clene's efforts to develop innovative therapies for neurodegenerative diseases, which could potentially impact the lives of patients with ALS and MS. Investors can gain valuable insights from the presentation at the conference, influencing their investment decisions.
Summary
Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. will present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase, focusing on treating neurodegenerative diseases like ALS and MS. The live webcast is scheduled for August 13, 2024, at 11:30 a.m. EST. To view the webcast, visit https://ibn.fm/uGo0W
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene to Present at Canaccord Genuity Conference
